NPR logo

Fate of 'BioShield' Bill for Anti-Terror Drugs Unclear

  • Download
  • <iframe src="https://www.npr.org/player/embed/1917656/1917657" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
Fate of 'BioShield' Bill for Anti-Terror Drugs Unclear

Science

Fate of 'BioShield' Bill for Anti-Terror Drugs Unclear

Fate of 'BioShield' Bill for Anti-Terror Drugs Unclear

  • Download
  • <iframe src="https://www.npr.org/player/embed/1917656/1917657" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Congress this week is expected to take up a $6 billion bill for developing tests, treatments and vaccines against bioterrorism. Known as Project BioShield, the plan aims to create research incentives for the private sector. But many drug and biotech firms say without protections from potential lawsuits, the bill won't do much to stimulate drug development. Hear NPR's Julie Rovner.

We no longer support commenting on NPR.org stories, but you can find us every day on Facebook, Twitter, email, and many other platforms. Learn more or contact us.